Ipca Labs announces global licensing collaboration with Bhami’s Research Laboratory for monoclonal antibodies

image credit- freepik

Mumbai-based Ipca Laboratories and Bhami’s Research Laboratory (BRL) have announced a definitive global licensing agreement granting Ipca access to BRL's proprietary high-concentration subcutaneous biologics delivery platform for the development and commercialisation of multiple monoclonal antibody products targeting oncology and inflammatory diseases.

BRL will receive defined milestone fee pertaining to the Technology Transfer, and Royalty on net sales upon commercialisation of the product. BRL is headquartered in Mangalore, with core expertise in protein and peptide drug delivery.  

Pranay Godha, MD & CEO, Ipca Laboratories said, “By pairing Ipca’s established science with BRL’s Novel Formulation Platform, we’re accelerating developing affordable biologics for people battling cancer and autoimmune disease worldwide.”

Surya Pai, CEO & Co-Founder, BRL said, “We are delighted to be expanding the reach of our novel, proprietary, patented subcutaneous protein delivery platform technology through this exciting partnership with Ipca to develop differentiated biologics for the global market. This strategic partnership is designed to make patient care convenient, affordable and safe."